Research Article

Association between Platelet to Neutrophil Ratio (PNR) and Clinical Outcomes in STEMI Patients after Successful pPCI: A Secondary Analysis Based on a Cohort Study

Hao Wang,¹ Xiaochun Qing,¹ Hua Wang,² and Yunfei Gu¹

¹Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
²Ultrasound Department, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China

Correspondence should be addressed to Yunfei Gu; yunfeigu@126.com

Received 11 November 2021; Accepted 14 February 2022; Published 24 February 2022

Academic Editor: Brian Tomlinson

Copyright © 2022 Hao Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. This study was aimed at investigating whether the platelet-to-neutrophil ratio (PNR) is independently related to the prognosis of patients with ST-elevation myocardial infarction (STEMI) after successful primary percutaneous coronary intervention (pPCI).

Methods. This was a secondary analysis of data retrieved from the DATADRYAD database, which was a prospective cohort study. A total of 464 STEMI patients who underwent successful pPCI were recruited between January 2010 and October 2014. The target-independent variable, PNR, was measured at the baseline. The dependent variable in the current study was the occurrence of major adverse cardiovascular events (MACEs) during the 30-month follow-up.

Results. Two patients were excluded from the final analysis because their platelet counts were unavailable. The average age of the 462 participants was 63 ± 11.92 years, and approximately 76.6% were male. After adjusting for age, sex, anterior wall myocardial infarction (MI), history of MI, apelin-12, apelin-12 change rate, left ventricular end-diastolic diameter, peak cardiac troponin I, pathological Q wave, Killip classification grade, fasting blood glucose, albumin, GENSINI score, and estimated glomerular filtration rate, a nonlinear relationship was found between the PNR and MACEs in the included cohort. The threshold value of the PNR for MACEs was 23.1. Over this cutoff value, the incidence rate of MACEs increased by 43% per 10-unit change in PNR (95% CI: 1.16–1.75, p = 0.0006).

Conclusion. There was a threshold relationship between PNR and MACEs in patients with STEMI who underwent successful pPCI. The incidence of MACEs was positively associated with the PNR when the PNR exceeded 23.1.

1. Introduction

ST-segment elevation myocardial infarction (STEMI) is the most severe type of heart attack [1]. It remains the most common cause of death in adults globally [2]. Although the rates of immediate STEMI-related deaths have declined because of technological advances and the widespread use of reperfusion therapy, the risk of mortality associated with STEMI remains high, especially for high-risk patients [3]. As indicated by the latest guidelines by the European Society of Cardiology (ESC) for the management of STEMI, the inhospital mortality and one-year mortality rates for STEMI are approximately 10% [4]. Post-STEMI survival is influenced by clinical factors, such as age, sex, infarct area, and biochemical factors [5]. Therefore, earlier identification of high-risk patients makes it possible to provide more aggressive treatment and closely monitor to those patients, especially after discharge. There is no doubt that this is of great significance.

Complete blood count (CBC) is the first test on admission for all patients. It is easy to perform, inexpensive, and rapid. Recently, the absolute blood cell counts or the ratios between them have received increased clinical attention as inflammatory markers [6–9]. The predictive value of the platelet-to-lymphocyte/neutrophil-to-lymphocyte ratio (PLR/NLR) and the systemic immune-inflammation index (platelet count × NLR) were demonstrated to affect the clinical outcomes of STEMI patients [8–13]. However, few studies have focused on the
Table 1: Clinical characteristic of participants.

|                      | Q1  | Q2  | Q3  | Q4  | p value | p value* |
|----------------------|-----|-----|-----|-----|---------|----------|
|                      | (N=116) | (N=115) | (N=115) | (N=116) |         |          |
| Age (years, mean ± sd) | 62.37 ± 11.45 | 63.22 ± 11.13 | 63.17 ± 13.01 | 63.13 ± 12.12 | 0.941   | 0.941    |
| Gender (male, n (%))  | 86 (74.14%) | 85 (73.91%) | 84 (73.04%) | 99 (85.34%) | 0.085   |          |
| HBP (n, %)            | 72 (62.07%) | 70 (60.87%) | 59 (51.30%) | 63 (54.31%) | 0.286   |          |
| DM (n, %)             | 38 (32.76%) | 41 (35.65%) | 30 (26.09%) | 40 (34.48%) | 0.409   |          |
| Myocardial infarction history (n, %) | 14 (12.07%) | 15 (13.04%) | 10 (8.70%) | 16 (13.79%) | 0.644   |          |
| Anterior wall myocardial infarction (n, %) | 60 (51.72%) | 45 (39.13%) | 64 (55.65%) | 61 (52.59%) | 0.062   |          |
| SBP (mmHg, mean ± sd) | 134.74 ± 25.37 | 130.06 ± 29.81 | 133.23 ± 26.00 | 129.29 ± 27.19 | 0.371   | 0.347    |
| HR (bpm, mean ± sd)  | 77.58 ± 17.69 | 75.44 ± 16.75 | 78.38 ± 17.41 | 76.42 ± 16.74 | 0.582   | 0.571    |
| WBC (×10³/L, mean ± sd) | 13.45 ± 2.58 | 11.36 ± 3.16 | 9.00 ± 2.38 | 6.52 ± 1.96 | <0.001  | <0.001   |
| Neutrophil (% mean ± sd) | 81.65 ± 9.41 | 75.32 ± 10.46 | 74.56 ± 10.36 | 71.33 ± 13.14 | <0.001  | <0.001   |
| Hemoglobin (g/L, mean ± sd) | 144.96 ± 16.95 | 143.28 ± 17.31 | 143.36 ± 17.57 | 143.49 ± 17.07 | 0.863   | 0.860    |
| Platelet (×10³/L, mean ± sd) | 192.69 ± 43.64 | 227.93 ± 52.12 | 239.54 ± 52.21 | 267.74 ± 49.61 | <0.001  | <0.001   |
| PNR                  | 17.95 ± 3.44 | 27.34 ± 2.47 | 36.59 ± 3.70 | 63.13 ± 21.88 | <0.001  | <0.001   |
| BUN (mmol/L, mean ± sd) | 6.80 ± 2.07 | 6.61 ± 1.98 | 6.89 ± 2.18 | 6.64 ± 2.08 | 0.703   | 0.680    |
| Creatinine (mmol/L, mean ± sd) | 72.38 ± 14.08 | 73.82 ± 15.93 | 76.80 ± 35.16 | 75.56 ± 19.68 | 0.473   | 0.839    |
| eGFR (mL/min × 1.73 m², mean ± sd) | 0.43 ± 0.12 | 0.42 ± 0.12 | 0.43 ± 0.15 | 0.42 ± 0.13 | 0.935   | 0.940    |
| Uric acid (mmol/L, mean ± sd) | 329.83 ± 74.30 | 342.32 ± 74.45 | 340.16 ± 71.65 | 336.20 ± 74.79 | 0.591   | 0.556    |
| Albumin (g/L, mean ± sd) | 37.26 ± 3.94 | 38.53 ± 3.58 | 38.41 ± 3.67 | 37.58 ± 4.05 | 0.029   | 0.040    |
| FBG (mmol/L, mean ± sd) | 7.34 ± 2.50 | 7.80 ± 2.50 | 7.93 ± 2.61 | 7.59 ± 2.51 | 0.309   | 0.275    |
| TG (mmol/L, median (quartile)) | 1.06 (0.61-1.56) | 1.00 (0.52-1.42) | 0.98 (0.59-1.54) | 1.07 (0.60-1.63) | 0.378   | 0.752    |
| TC (mmol/L, mean ± sd) | 5.78 ± 1.24 | 5.64 ± 1.12 | 5.55 ± 1.09 | 5.60 ± 1.09 | 0.477   | 0.344    |
| HDL-C (mmol/L, mean ± sd) | 1.20 ± 0.29 | 1.20 ± 0.25 | 1.18 ± 0.28 | 1.23 ± 0.28 | 0.646   | 0.496    |
| LDL-C (mmol/L, mean ± sd) | 3.19 ± 0.70 | 3.06 ± 0.71 | 2.89 ± 0.70 | 3.04 ± 0.77 | 0.018   | 0.012    |
| Peak cTnI (ng/mL, median (quartile)) | 17.45 (6.01-29.92) | 15.20 (3.97-30.00) | 12.50 (3.45-26.90) | 11.05 (4.62-30.40) | 0.376   | 0.337    |
| Peak CK-MB (U/L, median (quartile)) | 128.50 (63.50-215.50) | 112.00 (46.50-186.00) | 105.00 (37.50-182.50) | 94.50 (36.75-196.00) | 0.085   | 0.050    |
| D-Dimer (mg/L, median (quartile)) | 1.10 (0.40-1.80) | 0.90 (0.20-1.60) | 0.90 (0.20-1.50) | 0.80 (0.20-1.70) | 0.915   | 0.764    |
| LVEDD (mm, mean ± sd) | 50.81 ± 5.85 | 50.07 ± 5.94 | 49.77 ± 6.27 | 51.09 ± 6.97 | 0.335   | 0.262    |
| Apelin-12 change rate (% median (quartile)) | 12.00 (6.45-20.05) | 14.70 (5.35-20.60) | 15.50 (6.85-21.65) | 13.45 (4.72-20.15) | 0.451   | 0.472    |
| Apelin-12 (ng/mL, mean ± sd) | 0.84 ± 0.36 | 0.83 ± 0.32 | 0.84 ± 0.35 | 0.80 ± 0.32 | 0.792   | 0.708    |
association between the platelet-to-neutrophil ratio (PNR) and the prognosis of STEMI patients [8]. One research letter by Somaschini et al. suggested that the PNR may be associated with the prognosis of STEMI patients undergoing primary percutaneous coronary intervention (pPCI) [14]. Platelets are inducers and biomarkers of chronic inflammatory conditions such as atherosclerosis and atherothrombosis [15]. Neutrophils are acute inflammatory markers, as they are the first cells to be recruited to the myocardium under the condition of myocardial infarction [16]. To a certain extent, the PNR reflects the balance between chronic and acute inflammatory condition [14]. Therefore, this study aimed to investigate whether PNR is independently associated with the occurrence of major adverse cardiovascular events (MACEs) in patients with STEMI who underwent successful pPCI.

2. Participants and Methods

2.1. Data Source. The data used in the current study were obtained from an open-access database, DATADRYAD website (https://datadryad.org/), which allowed secondary analysis of their raw data with suitable citation [17]. The database included the following variables for further analysis: age, sex, hypertension, diabetes mellitus (DM), previous myocardial infarction (MI), anterior wall MI, systolic blood pressure (SBP), heart rate (HR), white blood cell (WBC) count, neutrophil percentage, hemoglobin, platelet count, blood urea nitrogen (BUN), creatinine, uric acid, albumin, fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), peak cardiac troponin I (cTnI), peak CK-MB levels, D-dimer levels, left ventricular end-diastolic diameter (LVEDD), apelin-12, apelin-12 change rate, culprit vessels, stent number, pathological Q wave, Killip classification grade, and GENSINI score. We calculated the PNR for every individual using the equation:

\[
\text{PNR} = \frac{\text{platelet count}}{\text{WBC} \times \text{percentage of neutrophils}} \tag{1}
\]

The estimated glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease (MDRD) equation adjusted for Chinese populations [18]:

\[
\text{eGFR (mL/s per 1.73 m}^2\text{)} = 175 \times (\text{serum creatinine in mmol/L})^{-1.234} \times (\text{age in years})^{-0.199} \times (0.79 \text{ if the patient was female}) \tag{2}
\]

2.2. Study Design and Population. The original study reported by Yang et al. was designed as a prospective cohort study to address the relationship between serum apelin-12 and MACEs (cardiac death, reinfarction of current culprit vessels, clinically driven target lesion revascularization (TLR), cardiogenic shock, and congestive heart failure) in STEMI patients after successful pPCI [17]. They consecutively enrolled STEMI patients who met the diagnostic criteria for STEMI and were admitted to the First People’s Hospital of Taizhou, Zhejiang, China, between January 2010 and October 2014. The diagnostic criteria included persistent chest pain beyond 30 minutes, ECG alterations, and elevated myocardial enzyme and troponin levels. All enrolled patients underwent successful standard pPCI as described by Yang et al. [17]. Written informed consent was obtained from each participant prior to data collection. After applying the exclusion criteria, 108 patients were excluded, as described by Yang et al. [17]. In the current study, we used PNR as the target-independent variable and found some predictive value for MACEs in a 30-month follow-up period. The covariates considered in this study comprised demographic data and potential variables that could affect PNR or MACEs based on previous studies and our clinical experience. The following variables were used in the fully

| PNR | Q1 (7.09-22.83) | Q2 (22.90-31.46) | Q3 (31.49-43.15) | Q4 (43.41-78.74) | p value | p value* |
|-----|----------------|----------------|----------------|----------------|---------|---------|
| Culprit vessels (n, %) | | | | | | |
| LAD | 62 (53.45%) | 52 (45.22%) | 59 (51.30%) | 58 (50.00%) | 0.254 | — |
| LCX | 22 (18.97%) | 23 (20.00%) | 14 (12.17%) | 13 (11.21%) | 0.949 | — |
| RCA | 32 (27.59%) | 40 (34.78%) | 42 (36.52%) | 45 (38.79%) | 0.055 | — |
| Stent number (mean ± sd) | 1.42 ± 0.59 | 1.37 ± 0.54 | 1.32 ± 0.49 | 1.41 ± 0.56 | 0.504 | 0.655 |
| Pathological Q wave (n, %) | 57 (49.14%) | 57 (49.57%) | 53 (46.09%) | 55 (47.41%) | 0.949 | — |
| Killip grade > 1 (n, %) | 34 (29.31%) | 19 (16.52%) | 34 (29.57%) | 25 (21.55%) | 0.055 | — |
| GENSINI | 76.32 ± 30.20 | 69.91 ± 33.32 | 69.57 ± 33.53 | 71.82 ± 31.77 | 0.360 | 0.361 |
| MACE (n, %) | 33 (28.45%) | 27 (23.48%) | 28 (24.35%) | 30 (25.86%) | 0.834 | — |
| Survival time (months, median (quartile)) | 25.04 (6.20-28.61) | 27.72 (15.79-29.25) | 23.12 (0.84-26.62) | 21.38 (0.51-25.82) | 0.228 | 0.006 |

Abbreviations: BUN: blood urea nitrogen; CK-MB: creatine kinase MB; cTnI: cardiac troponin I; eGFR: estimated glomerular filtration rate; FBG: fasting blood glucose; HDL-C: high-density lipoprotein cholesterol; LAD: left anterior descending branch; LCX: left circumflex coronary artery; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricular and diastolic diameter; MACEs: major adverse cardiovascular events; MI: myocardial infarction; RCA: right coronary artery; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride; WBC: white blood cells. *p value calculated by Kruskal-Wallis H test (skewed distribution).
### Table 2: The results of univariate analysis.

| Statistics | Effect size (HR, 95% CI) | p value |
|------------|--------------------------|---------|
| Age        | 66.95 ± 12.16            | 1.01 (0.99, 1.02) | 0.2427 |
| Gender     |                          |         |
| Female     | 33 (27.97%)              | Ref     |         |
| Male       | 85 (72.03%)              | 1.55 (1.03, 2.33) | 0.0353 |
| HBP        |                          |         |
| No         | 46 (38.98%)              | Ref     |         |
| Yes        | 72 (61.02%)              | 0.90 (0.62, 1.31) | 0.5881 |
| DM         |                          |         |
| No         | 77 (65.25%)              | Ref     |         |
| Yes        | 41 (34.75%)              | 0.86 (0.59, 1.27) | 0.4525 |
| Previous MI|                          |         |
| No         | 99 (83.90%)              | Ref     |         |
| Yes        | 19 (16.10%)              | 1.25 (0.76, 2.06) | 0.3739 |
| Anterior wall MI |                  |         |
| No         | 46 (38.98%)              | Ref     |         |
| Yes        | 72 (61.02%)              | 1.01 (0.69, 1.46) | 0.9723 |
| SBP        | 132.22 ± 26.59           | 1.00 (0.99, 1.01) | 0.8123 |
| HR         | 79.48 ± 18.51            | 1.00 (0.99, 1.02) | 0.3959 |
| WBC        | 10.60 ± 3.86             | 0.84 (0.79, 0.89) | <0.0001 |
| Neutrophil | 76.76 ± 12.56            | 1.01 (0.99, 1.02) | 0.3747 |
| Hemoglobin | 139.42 ± 16.66           | 1.00 (0.99, 1.01) | 0.9739 |
| Platelet   | 240.18 ± 60.08           | 1.00 (1.00, 1.00) | 0.3973 |
| PNR        | 34.90 ± 17.25            | 1.02 (1.01, 1.04) | <0.0001 |
| BUN        | 6.78 ± 1.88              | 0.97 (0.88, 1.07) | 0.5292 |
| Creatinine | 76.28 ± 15.64            | 1.02 (1.01, 1.03) | 0.0031 |
| eGFR       | 0.40 ± 0.12              | 0.21 (0.05, 0.91) | 0.0374 |
| Uric acid  | 333.34 ± 80.66           | 1.00 (1.00, 1.00) | 0.0440 |
| Albumin    | 37.88 ± 3.91             | 0.99 (0.94, 1.04) | 0.7218 |
| FBG        | 7.67 ± 2.68              | 0.96 (0.90, 1.03) | 0.2573 |
| TG         | 1.08 ± 0.65              | 0.86 (0.64, 1.14) | 0.2891 |
| TC         | 5.87 ± 0.99              | 1.16 (0.95, 1.41) | 0.1450 |
| HDL-C      | 1.25 ± 0.28              | 1.21 (0.59, 2.48) | 0.6058 |
| LDL-C      | 3.07 ± 0.72              | 0.92 (0.71, 1.21) | 0.5636 |
| Peak cTnI  | 18.47 ± 11.75            | 0.99 (0.98, 1.01) | 0.4161 |
| Peak CK-MB | 133.20 ± 88.07           | 1.00 (1.00, 1.00) | 0.9251 |
| D-dimer    | 0.97 ± 0.88              | 0.92 (0.73, 1.16) | 0.4907 |
| LVEDD      | 51.98 ± 6.39             | 1.03 (1.00, 1.06) | 0.0552 |
| Apelin-12  | 0.71 ± 0.28              | 0.74 (0.38, 1.43) | 0.3739 |
| Apelin-12 change rate |      | 1.01 (0.99, 1.03) | 0.4852 |
| Culprit vessels |                  |         |
| LAD        | 64 (54.24%)              | Ref     |         |
| LCX        | 18 (15.25%)              | 0.95 (0.56, 1.62) | 0.8642 |
| RCA        | 36 (30.51%)              | 1.18 (0.78, 1.78) | 0.4428 |
| Stent number | 1.35 ± 0.55              | 1.06 (0.73, 1.54) | 0.7415 |
adjusted model: age, sex, anterior wall MI, history of MI, apelin-12, apelin-12 change rate, LVEDD, peak cTnI level, pathological Q wave, Killip classification grade, FBG and albumin levels, GENSINI score, and eGFR screened by univariate analysis.

### 2.3. Statistical Analysis

Continuous variables are presented as mean ± standard deviation for normally distributed data or median (interquartile range [IQR]) for nonnormally distributed data. The Kolmogorov-Smirnov test was used to determine whether the data were normally distributed. Categorical variables were expressed as frequencies and percentages. Data was grouped based on quartiles of PNR values, and the differences among the groups were detected using $\chi^2$ (categorical variables), one-way ANOVA (for normally distributed data), or the Kruskal-Wallis H test for skewed distributed variables. The data analysis was based on the following principles: (1) whether any relationship exists between the PNR and MACEs and determining the nature of that relationship (linear or nonlinear), (2) estimating the factors affecting the association between PNR and the prognosis of STEMI patients, and (3) determining the true relationship between PNR and MACEs after adjustment for potential interference factors. The data analysis can be summarized in two steps. **Step 1:** Constructing three univariate and multivariate Cox proportional hazard models as follows: model 1, the crude model, in which no covariate was adjusted; model 2, the minimally adjusted model, in which only the age and sex were adjusted; and model 3, the fully adjusted model, in which all potential covariates screened out were added to model 2. During data analysis, the PNR was converted into a categorical variable (PNR quartiles) to confirm the stability of the results. To observe the existence of a nonlinear relationship, the trend of the $p$ values was obtained by calculating the regression coefficient of the $p$ values after substituting the median PNR values of the four groups using the Cox regression equation as a continuous variable. **Step 2:** If the nonlinearity was captured, a Cox proportional hazard regression model with cubic spline functions and smooth curve fitting (penalized spline method) was created. First, we calculated the inflection point using a recursive algorithm and then constructed a two-piecewise Cox proportional hazard model on both sides of the inflection point. Subsequently, the log-likelihood ratio test was used to verify the most suitable model for the association between PNR and MACEs. All analyses were performed using the statistical software R (https://www.R-project.org, The R Foundation) and EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA, USA). Statistical significance was set at $p < 0.05$ (two-sided).

### 3. Results

#### 3.1. Baseline Characteristics of the Selected Participants

After excluding two patients (ID 42 and 46) as their platelet counts were missing, the data of 462 patients (mean age, 63 ± 11.92 years; 76.6% were male, $n = 354$) were finally analyzed. The baseline characteristics of the participants are shown in Table 1, according to the PNR quartile. No significant differences were detected in most of the analyzed variables among the different PNR groups, except in the WBC count, neutrophil percentage, platelet count, LDL-C, albumin levels, and survival time. The participants with the highest PNR (43.41–78.74) had the shortest survival duration ($p = 0.006$).

#### 3.2. Univariate Analysis

In univariate analysis, male sex (HR = 1.55, 95% CI: 1.03–2.33), PNR (HR = 1.02, 95% CI: 1.01–1.04), stent number > 3 (HR = 4.63, 95% CI: 1.64–13.10), creatinine (HR = 1.02, 95% CI: 1.01–1.03), and uric acid (HR = 1.00, 95% CI: 1.00–1.00) were associated with an increase in MACEs (Table 2). The WBC level (HR = 0.84, 95% CI: 0.79–0.89) was negatively associated with MACEs.

#### 3.3. Unadjusted and Adjusted Cox Proportional Hazard Model

Three models were constructed as described previously to detect the independent effects of PNR on MACEs. The effect size of PNR was very stable among the different models, as shown in Table 3. For the sensitivity analysis, PNR was converted into a categorical variable (PNR quartiles), and the trend of $p$ values in different models was consistent with the result achieved with the continuous PNR values. Moreover, the trend of the effect size in the different PNR groups was nonequidistant, which indicated the possibility of nonlinearity.

#### 3.4. Nonlinearity of PNR and MACEs

A nonlinear relationship between PNR and MACEs was found in the current study after adjusting for age, sex, anterior wall MI, MI history, apelin-12, apelin-12 change rate, LVEDD, peak cTnI, pathological Q wave, Killip classification grade, FBG, and albumin levels, GENSINI score, and eGFR (Figure 1). The log likelihood ratio test $p$ value was $<0.05$; therefore, a two-
Unfortunately, the detailed results of that study are unavailable. We anticipate that more studies can further verify the results.

Table 3: Impacts of PNR on MACEs in different models.

| Variable | Crude model (HR, 95% CI, p)  | Minimally adjusted model (HR, 95% CI, p)  | Fully adjusted model (HR, 95% CI, p)  |
|----------|-----------------------------|------------------------------------------|--------------------------------------|
| PNR      | 1.03 (1.02, 1.05) <0.0001    | 1.03 (1.02, 1.04) <0.0001                 | 1.02 (1.00, 1.04) 0.0152             |
| PNR (quartile) |                     |                                           |                                      |
| Q1       | Ref                         | Ref                                       | Ref                                  |
| Q2       | 0.79 (0.47, 1.33) 0.3743    | 0.65 (0.38, 1.12) 0.1225                 | 0.64 (0.35, 1.18) 0.1500             |
| Q3       | 1.91 (1.13, 3.24) 0.0156    | 1.95 (1.15, 3.31) 0.0129                 | 1.69 (0.91, 3.14) 0.0971             |
| Q4       | 2.70 (1.55, 4.72) 0.0005    | 2.44 (1.39, 4.26) 0.0018                 | 2.04 (1.07, 3.88) 0.0307             |
| P for trend | 1.44 (1.19, 1.74) 0.0002    | 1.42 (1.17, 1.71) 0.0003                 | 1.29 (1.04, 1.61) 0.0223             |

Crude model: we did not adjust other covariates. Minimally adjusted model: we adjusted age and sex. Fully adjusted model: we adjusted age, sex, anterior wall myocardial infarction, myocardial infarction history, apelin-12, apelin-12 change rate, LVEDD, peak cTnI, pathological Q wave, Killip grade, FBG, albumin, GENSINI, and eGFR. CI confidence interval, Ref reference.

Figure 1: The impact of PNR on MACEs of STEMI patients after pPCI. A nonlinear relationship between them was detected after adjusting for age, sex, anterior wall myocardial infarction, myocardial infarction history, apelin-12, apelin-12 change rate, LVEDD, peak cTnI, pathological Q wave, Killip grade, FBG, albumin, GENSINI, and eGFR.

Table 4: The results of two-piecewise linear regression model.

| Inflection point of PNR | Effect size (HR) | 95% CI | p value |
|-------------------------|-----------------|--------|---------|
| <2.31                   | 0.57            | 0.29 to 1.13 | 0.1084 |
| ≥2.31                   | 1.43            | 1.16 to 1.75 | 0.0006 |

Effect: MACEs. Cause: PNR (per 10-unit change). Adjusted: age, sex, anterior wall myocardial infarction, myocardial infarction history, apelin-12, apelin-12 change rate, LVEDD, peak cTnI, pathological Q wave, Killip grade, FBG, albumin, GENSINI, and eGFR.

4. Discussion

Our findings indicated that PNR was positively associated with MACEs in STEMI patients who underwent successful pPCI after adjusting for confounding factors. Furthermore, the threshold effect was revealed through further analyses. To the best of our knowledge, this is the first report to provide a clear, quantified, nonlinear effect of PNR on the incidence of MACEs in post-pPCI STEMI patients.

Only one previous study has evaluated the relationship between the neutrophil-to-platelet ratio (NPR), which is the inverse of the PNR we investigated, and the short-term prognosis of STEMI after pPCI [14]. In that study, an NPR > 0.045 (which corresponds with PNR <22.2) was correlated with increased 30-day mortality in STEMI patients after pPCI [14]. Interestingly, we achieved a similar inflection point (23.1 in this study). We also observed a potentially negative trend when PNR < 23.1, although insignificant. Unfortunately, the detailed results of that study are unavailable; hence, further comparisons could not be performed. We anticipate that more studies can further verify the results of our study in future.

Atherosclerosis, chronic inflammation, and acute plaque disruption play essential pathological roles in most STEMI patients [19, 20]. The prognosis of patients with STEMI is influenced not only by the severity of acute local lesions but also by the preexisting and persistent chronic inflammatory condition of atherosclerosis [5, 16, 19]. Emerging studies have defined platelet as a type of immune and inflammatory cell [13, 15] involved in every pathological aspect of atherosclerosis [21–24]. Its level reflects the condition of preexisting inflammation in coronary artery disease (CAD). Meanwhile, neutrophil count is closely correlated with the severity of CAD [25–27]. In our study, PNR was positively associated with the long-term prognosis of STEMI after successful pPCI, which indicated that preexisting inflammatory conditions expressed by fluctuating platelet levels might play a relatively more important role than acute inflammatory reactions, which were expressed by neutrophils in STEMI. Our results, on the one hand, demonstrated the necessity of primary and secondary prevention of CAD; on the other hand, they might provide new approaches for the management of STEMI.
We recognize that this study had the following limitations: (1) This study was conducted on patients with STEMI who had undergone successful pPCI. Therefore, timely and effective revascularization by PCI might weaken the damage caused by acute injury and alleviate the impact of acute inflammation on clinical outcomes. (2) Since patients with NSTEMI were excluded from this study, the findings of this study cannot be used for these patients. (3) As data limited, no other detailed procedural data, such as incidence of no-reflow and application of thrombus aspiration, the potential influence brought by these limitations of secondary analysis could not be evaluated further. Fortunately, the original study reported that no significant difference existed between the MACE and non-MACE groups, which was also insignificant in the subsequent Cox regression. Furthermore, all enrolled patients underwent successful pPCI. This would, to some extent, alleviate possible heterogeneity among participants. Future research is needed to explore the influence of the balance between chronic inflammation and acute inflammation on the prognosis of patients with STEMI after undergoing pPCI.

5. Conclusion

There is a threshold relationship between PNR and MACEs in patients with STEMI after successful pPCI. The incidence of MACEs was positively associated with PNR when the PNR exceeded 23.1.

Data Availability

Data can be accessed from “DATADRYAD” database (https://datadryad.org/stash/dataset/doi:10.5061/dryad.pf56m).

Ethical Approval

The original study was approved by the Research Ethics Committee of The First People’s Hospital of Taizhou, and written informed consent was obtained from all participants.

Disclosure

This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Hao Wang and Xiaochun Qing contributed to data analysis, interpretation, and manuscript drafting. Hua Wang and Yunfei Gu help in data acquisition and manuscript revision. Yunfei Gu contributed to manuscript conception and final approval. Hao Wang and Xiaochun Qing contributed equally to this work. All the authors read and approved the final manuscript.

Acknowledgments

The authors thank all the staff members in our institution. The authors thank the data providers of this study. They completed the whole study. They are (the rankings and institutions of these researchers were ranked according to the original paper) Lingchang Yang, Ting Zheng, Haopeng Wu, Wenwei Xin, Xiongneng Mou, Hui Lin, Yide Chen, and Xiaoyu Wu (corresponding author) (Department of Emergency Medicine, The First People’s Hospital of Taizhou, Taizhou, Zhejiang, China). The authors also thank Changzhong Chen, Xinglin Chen, Chen Chi, Jie Liu, Wenjing Liu, Wenquan Liang, and Haibo Li of Yi-er College. This research was financially supported by the Medical and Health Project of Science and Technology of Luoyang City (2020003A).

References

[1] M. Yildiz, S. R. Wade, and T. D. Henry, “STEMI care 2021: addressing the knowledge gaps,” American Heart Journal Plus: Cardiology Research and Practice, vol. 11, article 100044, 2021.

[2] N. Townsend, L. Wilson, P. Bhatnagar, K. Wickramasinghe, M. Rayner, and M. Nichols, "Cardiovascular disease in Europe: epidemiological update 2016," European Heart Journal, vol. 37, no. 42, pp. 3232–3245, 2016.

[3] C. P. Gale, V. Allan, B. A. Cattle et al., “Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003-2010: a multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR),” Heart, vol. 100, no. 7, pp. 582–589, 2014.

[4] B. Ibnez, S. James, S. Agewall et al., “2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 39, no. 2, pp. 119–177, 2018.

[5] F. Pedersen, V. Butrymovich, H. Kelbæk et al., “Short- and long-term cause of death in patients treated with primary PCI for STEMI,” Journal of the American College of Cardiology, vol. 64, no. 20, pp. 2101–2108, 2014.

[6] W. Xiong, M. Xu, Y. Zhao, X. Wu, B. Pudasaini, and J. M. Liu, “Can we predict the prognosis of COPD with a routine blood test?,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 12, pp. 615–625, 2017.

[7] H. Sun, C. Q. Yin, Q. Liu, F. Wang, and C. H. Yuan, “Clinical significance of routine blood test-associated inflammatory index in breast cancer patients,” Medical Science Monitor, vol. 23, pp. 5090–5095, 2017.

[8] H. Haybar, S. M. S. Pezeski, and N. Saki, “Evaluation of complete blood count parameters in cardiovascular diseases: an early indicator of prognosis?,” Experimental and Molecular Pathology, vol. 110, article 104267, 2019.

[9] A. M. Adam, A. H. Rizvi, A. Haq et al., “Prognostic value of blood count parameters in patients with acute coronary syndrome,” Indian Heart Journal, vol. 70, no. 2, pp. 233–240, 2018.

[10] C. Gao, D. Zhao, J. Wang, P. Liu, and B. Xu, “Clinical significance and correlation of microRNA-21 expression and the neutrophil-lymphocyte ratio in patients with acute myocardial infarction,” Clinics, vol. 74, article e1237, 2019.
[11] E. Ricottini, F. Mangiacapra, A. Nusca et al., “Relation of platelet indexes to platelet reactivity and periprocedural myocardial infarction in patients who underwent percutaneous coronary angioplasty,” *The American Journal of Cardiology*, vol. 121, no. 9, pp. 1027–1031, 2018.

[12] H. Li, Y. Zhou, Y. Ma, S. Han, and L. Zhou, “The prognostic value of the platelet-to-lymphocyte ratio in acute coronary syndrome: a systematic review and meta-analysis,” *Kardiologia Polska*, vol. 75, no. 7, pp. 666–673, 2017.

[13] K. Esenboğa, A. Kurtul, Y. Y. Yamantürk, T. S. Tan, and D. E. Tutar, “Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention,” *Acta Cardiologica*, pp. 1–8, 2021.

[14] A. Somaschini, S. Cornara, A. Demarchi et al., “Neutrophil to platelet ratio: a novel prognostic biomarker in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention,” *European Journal of Preventive Cardiology*, vol. 27, no. 19, pp. 2338–2340, 2020.

[15] C. N. Morrell, A. A. Aggrey, L. M. Chapman, and K. L. Modjeski, “Emerging roles for platelets as immune and inflammatory cells,” *Blood*, vol. 123, no. 18, pp. 2759–2767, 2014.

[16] V. Fineschi, “Measuring myocyte oxidative stress and targeting cytokines to evaluate inflammatory response and cardiac repair after myocardial infarction,” *Current Vascular Pharmacology*, vol. 13, no. 1, pp. 3–5, 2015.

[17] L. Yang, T. Zheng, H. Wu et al., “Predictive value of apelin-12 in patients with ST-elevation myocardial infarction with different renal function: a prospective observational study,” *BMJ Open*, vol. 7, no. 11, article e018595, 2017.

[18] Y. C. Ma, L. Zuo, J. H. Chen et al., “Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease,” *Journal of the American Society of Nephrology*, vol. 17, no. 10, pp. 2937–2944, 2006.

[19] P. M. Ridker, B. M. Everett, T. Thuren et al., “Antiinflammatory therapy with canakinumab for atherosclerotic disease,” *The New England Journal of Medicine*, vol. 377, no. 12, pp. 1119–1131, 2017.

[20] R. Ross, “Atherosclerosis—an inflammatory disease,” *The New England Journal of Medicine*, vol. 340, no. 2, pp. 115–126, 1999.

[21] L. Badimon, T. Padró, and G. Villahur, “Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease,” *European Heart Journal Acute Cardiovascular Care*, vol. 1, no. 1, pp. 60–74, 2012.

[22] T. J. Barrett, M. Schlegel, F. Zhou et al., “Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis,” *Science Translational Medicine*, vol. 11, no. 517, article eaax0481, 2019.

[23] T. I. Siddiqui, K. S. A. Kumar, and D. K. Dikshit, “Platelets and atherothrombosis: causes, targets and treatments for thrombosis,” *Current Medicinal Chemistry*, vol. 20, no. 22, pp. 2779–2797, 2013.

[24] Y. Huo and K. F. Ley, “Role of platelets in the development of atherosclerosis,” *Trends in Cardiovascular Medicine*, vol. 14, no. 1, pp. 18–22, 2004.

[25] J. García-Prieto, R. Villena-Gutiérrez, M. Gómez et al., “Neutrophil stunning by metoprolol reduces infarct size,” *Nature Communications*, vol. 8, no. 1, article 14780, 2017.